TenNor Therapeutics Received Government Grant to Support Development of Dua-Action Molecules for the Treatment of MDR/XDR-TB.

TenNor Therapeutics has received a new drug innovation grant under the 12th five-year plan to support the development of dual-action molecules for the treatment of MDR/XDR-TB. As part of a consortium of academic and industry partnership led by Institute of Materia Medica of Chinese Academy of Medical Sciences, TenNor will utilize its proprietary dual-action molecular technology to advance a novel series of dual-action compounds for the treatment of drug-resistant tuberculosis. The TenNor team led by Founder and CEO Dr. Zhenkun Ma attended the project kick-off meeting in Beijing on January 25, 2016. Dr. Ma was appointed as a member of the Project Scientific Advisory Committee and gave a talk on New TB Drug Development Strategy and Pipeline. On behalf of TenNor Therapeutics, Dr. David Wan provided a project update during the meeting.

About TenNor Therapeutics

TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of differentiated new drug products in diseases associated with bacterial infection and metabolism. TenNor possesses a unique multi-targeting drug conjugate technology platform and a strong new drug development pipeline with global IP protection. Several products are currently in late stage of clinical development, targeting H. pylori infection, implanted medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company is committed to address the unmet needs in the disease area and provide safe and effective therapies for patients in China and around the world.

For more information, please visit: www.tennorx.com